Primary hyperparathyroidism - caused by a single adenoma (>80%) or diffuse hyperplasia of the parathyroid glands (15-20%)
Tertiary hyperparathyroidism
Malignant disease
Metastatic bone destruction
PTHrp from solid tumours
Osteoclast activating factors produced by tumours
Genetic syndromes
MEN1 and 2 - will almost always have developed a parathyroid adenoma with hypercalcaemia at a young age
Familial isolated hyperparathyroidism - adenoma as in primary hyperparathyroidism
Familial hypocalciuric hypercalcaemia - autosomal dominant deactivating mutation in the calcium sensing receptor which results in decreased sensitivity of the receptor to calcium
Usually benign/asymptomatic
Others
Drugs - Vit. D, thiazides
Granulomatous disease e.g. sarcoid, TB
High turnover - bedridden, thyrotoxic, Pagets
Clinical presentation
General
Gallstones (STONES)
Bone pain (BONES)
Abdominal pain (GROANS)
Psychiatric disturbances (PSYCHIC MOANS)
Acute
Thirst
Dehydration
Confusion
Polyuria
Chronic
Myopathy
Fractures
Osteopaenia
Depression
Hypertension
Pancreatitis
Duodenal ulcers
Renal calculi
Investigations
Biochemistry
Raised calcium
Serum PTH
Hallmark of primary hyperparathyroidism is hypercalcaemia and hypophosphataemia with detectable or elevated intact PTH levels during hypercalcaemia
Undetectable PTH with hypercalcaemia requires further investigation for malignancy
Serum alkaline phosphatase - raised in hypercalcaemia of malignancy
Imaging for malignancy
X-ray, CT, MRI, PET
Isotope bone scan
Familial hypocalciuric hypercalcaemia
Bloods - mild hypercalcaemia, reduced urine calcium excretion, PTH may be (marginally) elevated
Genetic screening
Management
Management of acute severe hypercalcaemia
Fluids - rehydrate with 0.9% saline 4-6L in 24 hours
Consider loop diurectics once rehydrated (avoid thiazides)
Bisphosphonates - single dose will lower Ca2+ over 2-3 days, max. effect at 1 week
Steriods occasionally used e.g. prednisolone 40-60mg/day for sarcoidosis
Primary hyperparathyroidism
Surgery (not always required) - indications include end organ damage, calcium >2.85 mmol/l, under age 50 and reduced eGFR (< 60 mL/min)
Cinacalcet - calcium mimetic, reduces PTH
Can be useful if need treatment but unfit for surgery
Licenced but not SMC approved
Approved for tertiary hyperparathyroidism and parathyroid carcinoma
Malignancy
Treat underlying malignancy
Chemotherapy may reduce calcium in malignant disease e.g. myeloma